Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new therapeutic class of oncolytic poxviruses has recently been developed that combines targeted and armed approaches for treating cancer. Using vaccinia virus as an example, this Perspective describes their mechanisms of action and promising clinical results.
Inhibition of kinase activity has received enormous interest as a therapeutic strategy for cancer. This Review discusses the current approaches to develop and characterize new inhibitors.